New drug combo targets tough blood cancers in early trial
NCT ID NCT01905813
First seen Jan 11, 2026 · Last updated May 01, 2026 · Updated 20 times
Summary
This early-phase study tests a new drug, INCB040093, alone or with another drug (itacitinib) in 121 adults with B-cell blood cancers that have come back or not responded to prior treatment. The main goal is to find safe doses and check for side effects. Researchers will also look for signs that the drugs are shrinking tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B CELL MALIGNANCIES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Study site
Birmingham, Alabama, United States
-
Study site
Jacksonville, Florida, United States
-
Study site
Ann Arbor, Michigan, United States
-
Study site
Rochester, Minnesota, United States
-
Study site
New York, New York, United States
-
Study site
Rochester, New York, United States
Conditions
Explore the condition pages connected to this study.